PT3527670T - Biogénese de mirna em exossomas para diagnóstico e terapia - Google Patents
Biogénese de mirna em exossomas para diagnóstico e terapiaInfo
- Publication number
- PT3527670T PT3527670T PT191512201T PT19151220T PT3527670T PT 3527670 T PT3527670 T PT 3527670T PT 191512201 T PT191512201 T PT 191512201T PT 19151220 T PT19151220 T PT 19151220T PT 3527670 T PT3527670 T PT 3527670T
- Authority
- PT
- Portugal
- Prior art keywords
- exosomes
- diagnosis
- therapy
- mirna biogenesis
- biogenesis
- Prior art date
Links
- 230000008436 biogenesis Effects 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 210000001808 exosome Anatomy 0.000 title 1
- 108091070501 miRNA Proteins 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
- G01N2333/4704—Inhibitors; Supressors
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361791301P | 2013-03-15 | 2013-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3527670T true PT3527670T (pt) | 2024-01-18 |
Family
ID=51581257
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT191512201T PT3527670T (pt) | 2013-03-15 | 2014-03-14 | Biogénese de mirna em exossomas para diagnóstico e terapia |
Country Status (15)
Country | Link |
---|---|
US (2) | US20160024503A1 (pt) |
EP (2) | EP2971162B1 (pt) |
JP (2) | JP6554458B2 (pt) |
KR (1) | KR102183406B1 (pt) |
CN (2) | CN109852695B (pt) |
AU (2) | AU2014239309B2 (pt) |
BR (1) | BR112015023275B1 (pt) |
CA (2) | CA2905081C (pt) |
ES (1) | ES2966571T3 (pt) |
HK (1) | HK1218143A1 (pt) |
IL (2) | IL241409B (pt) |
MX (2) | MX2015013141A (pt) |
PT (1) | PT3527670T (pt) |
RU (2) | RU2644247C2 (pt) |
WO (1) | WO2014152622A1 (pt) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016150475A1 (en) * | 2015-03-22 | 2016-09-29 | Universite De Liege | Circulating micrornas for the diagnosis of breast cancer |
CN104774966B (zh) * | 2015-05-01 | 2017-07-28 | 北京博奥医学检验所有限公司 | 肺腺癌miRNA标记物 |
BR112017026467A2 (pt) | 2015-06-10 | 2018-09-11 | Univ Texas | uso de exossomos para o tratamento de doença |
CN107151661A (zh) * | 2016-03-02 | 2017-09-12 | 上海润腾生物科技有限公司 | 一种人外泌体蛋白、试剂盒及其应用 |
CN106202984B (zh) * | 2016-08-26 | 2018-09-04 | 赵毅 | 一种基于多层复杂网络对肿瘤miRNA标志物的筛选方法 |
US20200063208A1 (en) * | 2016-10-13 | 2020-02-27 | University Of Louisville Research Foundation, Inc. | Exosomal biomarkers for diagnosis and prognosis of cancer and related methods |
CN110024037B (zh) | 2016-11-30 | 2023-06-27 | 微软技术许可有限责任公司 | 经由连接的dna随机存取存储系统 |
US10793897B2 (en) * | 2017-02-08 | 2020-10-06 | Microsoft Technology Licensing, Llc | Primer and payload design for retrieval of stored polynucleotides |
EP3717660A4 (en) * | 2017-11-30 | 2021-10-27 | Provincial Health Services Authority | METHOD OF EVALUATION OF HEAD AND NECK CANCER |
JP2021519283A (ja) | 2018-03-29 | 2021-08-10 | テクニオン・リサーチ・アンド・ディベロップメント・ファウンデーション・リミテッド | Pten阻害剤を含む小胞およびその使用 |
WO2019201277A1 (en) * | 2018-04-17 | 2019-10-24 | Wang Mong Lien | Method for blocking stress-induced tumor progression |
EP3786307A4 (en) * | 2018-04-25 | 2022-08-24 | Toray Industries, Inc. | KIT, DEVICE AND METHOD FOR DETECTION OF BLADDER CANCER |
WO2020080387A1 (ja) | 2018-10-17 | 2020-04-23 | 合同会社みらか中央研究所 | 細胞外小胞の回収方法 |
US11766484B2 (en) | 2019-01-03 | 2023-09-26 | International Business Machines Corporation | Exosome vessels for delivery of molecular cargo |
US20220136011A1 (en) | 2019-02-08 | 2022-05-05 | Board Of Regents, The University Of Texas System | Telomerase-containing exosomes for treatment of diseases associated with aging and age-related organ dysfunction |
WO2020163553A1 (en) * | 2019-02-08 | 2020-08-13 | Virginia Commonwealth University | Mda-7/il-24 for cancer treatment and methods of monitoring same |
WO2020175898A1 (ko) * | 2019-02-26 | 2020-09-03 | 서울대학교 산학협력단 | Tut4/7 발현 조절인자를 포함하는 암 예방 또는 치료용 약학적 조성물 |
WO2021003403A1 (en) * | 2019-07-02 | 2021-01-07 | Ohio State Innovation Foundation | Neurodegenerative disease therapies utilizing the skin-brain axis |
WO2021006279A1 (en) * | 2019-07-08 | 2021-01-14 | Preferred Networks, Inc. | Data processing and classification for determining a likelihood score for breast disease |
CN110358835A (zh) * | 2019-07-26 | 2019-10-22 | 泗水县人民医院 | 生物标志物在胃癌检测、诊断中的应用 |
KR102212699B1 (ko) * | 2019-08-12 | 2021-02-05 | 한국원자력의학원 | 유방암 예방 또는 치료용 조성물 |
CN110607361A (zh) * | 2019-10-08 | 2019-12-24 | 南京市儿童医院 | miR-431作为靶点在制备促进SP表达的药物中的应用 |
JPWO2021132213A1 (pt) | 2019-12-23 | 2021-07-01 | ||
EP3862441A3 (en) * | 2020-02-04 | 2021-10-27 | Artemisia S.p.A. | Method for the early diagnosis of cancer by means of ddpcr analysis of mirna and protein markers in liquid biopsy |
EP3862442A3 (en) * | 2020-02-04 | 2021-10-27 | Artemisia S.p.A. | Method for the early diagnosis of cancer by means of ddpcr analysis of mirna in liquid biopsy |
KR102318328B1 (ko) * | 2020-04-13 | 2021-10-27 | 고려대학교 산학협력단 | Gcc2 단백질을 과발현하는 엑소좀 기반 암 진단 또는 예후 예측용 마커 조성물 |
US20230227916A1 (en) | 2020-04-15 | 2023-07-20 | H.U. Group Research Institute G.K. | Method for recovering extracellular vesicle |
CN111920961B (zh) * | 2020-08-14 | 2023-09-08 | 福建医科大学附属协和医院 | 一种治疗癌症的药物 |
JP2023540426A (ja) * | 2020-09-08 | 2023-09-25 | ウロテック. カンパニー リミテッド | 前立腺癌診断スコアを算出するための方法及びそれの使用 |
KR102497196B1 (ko) | 2020-09-08 | 2023-02-07 | (주)유로테크 | 전립선암 진단 점수 계산 방법 및 그 용도 |
JP7460203B2 (ja) | 2020-11-11 | 2024-04-02 | 国立研究開発法人物質・材料研究機構 | 細胞で産生された膜小胞に由来する塩基配列を解析する方法、その装置、及び、そのプログラム |
CN112662752B (zh) * | 2021-01-18 | 2022-08-23 | 中国农业大学 | 一种诊断用生物标志物的应用 |
CN112760381B (zh) * | 2021-02-08 | 2022-11-01 | 复旦大学附属中山医院 | 一种检测肺腺癌预后的miRNA试剂盒 |
KR102310302B1 (ko) * | 2021-02-08 | 2021-10-06 | 을지대학교 산학협력단 | 엑소좀 기반 방광암 진단을 위한 정보 제공 방법 |
CN116121377A (zh) * | 2022-11-01 | 2023-05-16 | 山西医科大学 | 一种食管鳞癌外泌体富含的miRNA作为诊断食管鳞癌的标志物中的应用 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030064949A1 (en) | 1998-02-17 | 2003-04-03 | Loretta Nielsen | Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms |
FR2766205B1 (fr) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
KR100519384B1 (ko) | 2002-08-13 | 2005-10-06 | (주)누백스 | 유전자 이입을 이용한 엑소좀의 제조방법 및 상기 엑소좀의 용도 |
CN1281279C (zh) * | 2004-09-16 | 2006-10-25 | 浙江大学 | 针对表皮生长因子基因的小干扰核糖核酸分子及其用途 |
WO2009015357A1 (en) * | 2007-07-25 | 2009-01-29 | University Of Louisville Research Foundation, Inc. | Exosome-associated microrna as a diagnostic marker |
EP3112464A1 (en) * | 2007-09-14 | 2017-01-04 | The Ohio State University Research Foundation | Mirna expression in human peripheral blood microvesicles and uses thereof |
ES2588705T3 (es) * | 2007-09-27 | 2016-11-04 | Immunovaccine Technologies Inc. | Uso de liposomas en un vehículo que comprende una fase hidrófoba continua para la entrega de polinucleótidos in vivo |
ES2936256T3 (es) | 2008-02-01 | 2023-03-15 | Massachusetts Gen Hospital | Uso de microvesículas en el diagnóstico, y pronóstico de enfermedades y afecciones médicas |
EP3112477A1 (en) * | 2008-02-28 | 2017-01-04 | The Ohio State University Research Foundation | Microrna-based methods and compositions for the diagnosis, prognosis and treatment of prostate related disorders |
US20110172295A1 (en) * | 2008-04-11 | 2011-07-14 | The University Of North Carolina At Chapel Hill | METHODS AND COMPOSITIONS FOR THE REGULATION OF microRNA PROCESSING |
JP2011524164A (ja) | 2008-06-06 | 2011-09-01 | サントル・ナシオナル・ドウ・ラ・ルシエルシユ・シアンテイフイク(セー・エヌ・エール・エス) | 小分子rnaに基づく治療および診断ならびに小分子rnaの実験的研究におけるエンドリソソーム系および分泌小胞(エキソソーム様)の用途 |
WO2010056337A2 (en) * | 2008-11-12 | 2010-05-20 | Caris Mpi, Inc. | Methods and systems of using exosomes for determining phenotypes |
BR112012025593A2 (pt) * | 2010-04-06 | 2019-06-25 | Caris Life Sciences Luxembourg Holdings | biomarcadores em circulação para doença |
US10081542B2 (en) * | 2010-04-20 | 2018-09-25 | University of Florida Research Foundation, lnc. | Nanozymes, methods of making nanozymes, and methods of using nanozymes |
ES2629502T3 (es) * | 2011-03-11 | 2017-08-10 | Children's Medical Center Corporation | Métodos y composiciones relacionados con exosomas de células madre mesenquimales |
AU2012245188A1 (en) * | 2011-04-20 | 2013-12-05 | Smith, Larry J | Methods and compositions for modulating gene expression using components that self assemble in cells and produce RNAi activity |
EP2742154A4 (en) * | 2011-08-08 | 2015-08-12 | Caris Life Sciences Switzerland Holdings Gmbh | BIOMARKER COMPOSITIONS AND METHODS |
US9777042B2 (en) | 2011-12-15 | 2017-10-03 | Morehouse School Of Medicine | Method of purifying HIV/SIV Nef from exosomal fusion proteins |
WO2015085096A1 (en) | 2013-12-04 | 2015-06-11 | Board Of Regents, The University Of Texas System | Analysis of genomic dna, rna, and proteins in exosomes for diagnosis and theranosis |
EP4101859A1 (en) * | 2016-09-02 | 2022-12-14 | Dicerna Pharmaceuticals, Inc. | 4'-oxymethylphosphonate nucleotide analogs and oligonucleotides comprising the same |
-
2014
- 2014-03-14 WO PCT/US2014/027541 patent/WO2014152622A1/en active Application Filing
- 2014-03-14 RU RU2015144212A patent/RU2644247C2/ru active
- 2014-03-14 RU RU2018101152A patent/RU2018101152A/ru not_active Application Discontinuation
- 2014-03-14 EP EP14770497.7A patent/EP2971162B1/en active Active
- 2014-03-14 BR BR112015023275-2A patent/BR112015023275B1/pt active IP Right Grant
- 2014-03-14 MX MX2015013141A patent/MX2015013141A/es active IP Right Grant
- 2014-03-14 CN CN201910120129.9A patent/CN109852695B/zh active Active
- 2014-03-14 CA CA2905081A patent/CA2905081C/en active Active
- 2014-03-14 JP JP2016502475A patent/JP6554458B2/ja active Active
- 2014-03-14 AU AU2014239309A patent/AU2014239309B2/en active Active
- 2014-03-14 CN CN201480022292.7A patent/CN105264092B/zh active Active
- 2014-03-14 EP EP19151220.1A patent/EP3527670B1/en active Active
- 2014-03-14 PT PT191512201T patent/PT3527670T/pt unknown
- 2014-03-14 ES ES19151220T patent/ES2966571T3/es active Active
- 2014-03-14 CA CA3209023A patent/CA3209023A1/en active Pending
- 2014-03-14 KR KR1020157028765A patent/KR102183406B1/ko active IP Right Grant
- 2014-03-14 US US14/775,716 patent/US20160024503A1/en not_active Abandoned
-
2015
- 2015-09-09 IL IL241409A patent/IL241409B/en active IP Right Grant
- 2015-09-15 MX MX2020005165A patent/MX2020005165A/es unknown
-
2016
- 2016-05-30 HK HK16106127.5A patent/HK1218143A1/zh unknown
-
2018
- 2018-06-06 JP JP2018108450A patent/JP6807351B2/ja active Active
-
2020
- 2020-03-23 US US16/827,343 patent/US11926824B2/en active Active
- 2020-04-06 IL IL273829A patent/IL273829B/en unknown
- 2020-06-01 AU AU2020203590A patent/AU2020203590B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL273829B (en) | mirna biogenesis in the exosome for therapy and diagnosis | |
HK1222530A1 (zh) | 用於皮膚處理的微閉合及相關方法 | |
HK1207075A1 (en) | Glucopyranosyl derivatives and their uses in medicine | |
IL242770B (en) | A therapeutic combination that includes oxazolidinone-quinolones for use in the treatment of bacterial infections | |
GB2516343B (en) | Improvements in and relating to ophthalmoscopes | |
HK1222562A1 (zh) | 用於醫學診斷的組合物及方法 | |
IL239904A0 (en) | Inhibitory oligonucleotides and their use in therapy | |
GB2515865B (en) | Use of galactooligosaccharides in therapy | |
SG11201600013WA (en) | Systems and methods for in vivo irradiation of blood | |
GB201308753D0 (en) | Compounds and their use in therapy | |
HK1209033A1 (zh) | 奧地帕西在治療黏多醣症病中的應用 | |
ZA201503834B (en) | Identifying subjects in need of treatment | |
GB201309498D0 (en) | Novel diagnosis and therapy | |
GB201308217D0 (en) | Compounds and their use in therapy | |
GB201320958D0 (en) | Improvements in and relating to medical devices | |
GB201312129D0 (en) | Drug combination and its use in therapy | |
GB201312131D0 (en) | Drug combination and its use in therapy | |
GB201312128D0 (en) | Drug combination and its use in therapy | |
EP2994110A4 (en) | OPHTHALMIC RINSE AGENT AND ASSOCIATED METHODS | |
GB201302884D0 (en) | Novel methods for diagnosis and therapy | |
GB201322958D0 (en) | Uses of oligouronates in cancer treatment | |
AU2013901916A0 (en) | An Agent and Use Thereof in Therapy |